Biosimilar breast cancer drug trial pulled before it began
NCT ID NCT06884254
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 31 times
Summary
This study aimed to compare a biosimilar version of pertuzumab (EG1206A) to the original drug (Perjeta) in people with HER2-positive, hormone receptor-negative early breast cancer. Participants would have received either drug alongside trastuzumab and chemotherapy before surgery, then continued treatment after surgery. However, the trial was withdrawn before enrolling any patients, so no data were collected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EARLY BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Methodist Health System Clinical Research Institute
Dallas, Texas, 75023, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pertuzumab (biosimilar EG1206A)
What this could lead to
If successful, this could provide a more affordable biosimilar option for treating HER2-positive breast cancer.
What could go wrong
The study was withdrawn before any participants enrolled, so no results are available. Biosimilars may differ slightly in effectiveness or safety from the original drug.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.